To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


View sample alert

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Non-Departmental Publication (Policy paper)
Medicines and Healthcare products Regulatory Agency

Apr. 30 2024

Source Page: Impact of AI on the regulation of medical products
Document: Impact of AI on the regulation of medical products (webpage)

Found: Impact of AI on the regulation of medical products


Non-Departmental Publication (Policy paper)
Medicines and Healthcare products Regulatory Agency

Apr. 30 2024

Source Page: Impact of AI on the regulation of medical products
Document: (PDF)

Found: Impact of AI on the regulation of medical products


Public Bill Committees
Tobacco and Vapes Bill (Second sitting)
Committee stage: 2nd sitting - Tue 30 Apr 2024
Department of Health and Social Care

Mentions:
1: Angela Richardson (Con - Guildford) As the chief medical officer has said repeatedly, the tobacco industry marketing vapes to kids is completely - Speech Link
2: Preet Kaur Gill (LAB - Birmingham, Edgbaston) standards works and how you share information between the Medicines and Healthcare products Regulatory - Speech Link
3: Preet Kaur Gill (LAB - Birmingham, Edgbaston) They are not just litter; they are electronic devices and are very damaging with lots of chemicals inside - Speech Link
4: Mary Glindon (Lab - North Tyneside) Disposable electronic devices should not exist, and that is really important. - Speech Link
5: Mary Kelly Foy (Lab - City of Durham) I know that, in Durham, all sorts of electronic devices are thrown in the river, and that is interfering - Speech Link


Written Question
Medicines and Healthcare Products Regulatory Agency: Accountability
Tuesday 30th April 2024

Asked by: Rachael Maskell (Labour (Co-op) - York Central)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how the Medicines and Healthcare products Regulatory Agency is held accountable for its decisions.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care, under United Kingdom legislation, relating to the regulation of medicines, medical devices, and blood products for transfusion. The MHRA also performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care in relation to the standardisation and control of biological medicines including vaccines, blood products, and other substances which cannot be characterised chemically, and which require special testing measures to ensure their safety and efficacy.

My Rt hon. Friend, the Secretary of State for Health and Social Care has ministerial responsibility for, and oversight of, the MHRA’s delivery and performance. The MHRA seeks ministerial agreement for policy and legislative framework changes. Ministers are not involved in individual decisions made by the MHRA. The MHRA is held to account through regular established mechanisms including quarterly and annual accountability reviews. A framework agreement between the Department and the MHRA also sets out the governance structure within which both parties operate, with further information available at the following link:

https://www.gov.uk/government/publications/dh-and-mhra-framework-agreement/framework-agreement-between-dhsc-and-the-medicines-and-healthcare-products-regulatory-agency

The MHRA also publishes performance figures each month, as well as its annual report and accounts, and the minutes of the latest Annual Accountability Review with the MHRA is available at the following link:

https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023


Written Question
Medicines and Healthcare Products Regulatory Agency
Tuesday 30th April 2024

Asked by: Rachael Maskell (Labour (Co-op) - York Central)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps is she taking to review the decisions of the Medicines and Healthcare products Regulatory Agency.

Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care, under United Kingdom legislation, relating to the regulation of medicines, medical devices, and blood products for transfusion. The MHRA also performs the functions of my Rt hon. Friend, the Secretary of State for Health and Social Care in relation to the standardisation and control of biological medicines including vaccines, blood products, and other substances which cannot be characterised chemically, and which require special testing measures to ensure their safety and efficacy.

My Rt hon. Friend, the Secretary of State for Health and Social Care has ministerial responsibility for, and oversight of, the MHRA’s delivery and performance. The MHRA seeks ministerial agreement for policy and legislative framework changes. Ministers are not involved in individual decisions made by the MHRA. The MHRA is held to account through regular established mechanisms including quarterly and annual accountability reviews. A framework agreement between the Department and the MHRA also sets out the governance structure within which both parties operate, with further information available at the following link:

https://www.gov.uk/government/publications/dh-and-mhra-framework-agreement/framework-agreement-between-dhsc-and-the-medicines-and-healthcare-products-regulatory-agency

The MHRA also publishes performance figures each month, as well as its annual report and accounts, and the minutes of the latest Annual Accountability Review with the MHRA is available at the following link:

https://www.gov.uk/government/publications/annual-accountability-review-mhra/annual-accountability-review-minutes-2022-to-2023-3-july-2023


Departmental Publication (Open consultation)
Department for Work and Pensions

Apr. 29 2024

Source Page: Modernising support for independent living: the health and disability green paper
Document: Large print: Modernising support for independent living: the health and disability green paper (PDF)

Found: Modernising support for independent living: the health and disability green paper


Departmental Publication (Open consultation)
Department for Work and Pensions

Apr. 29 2024

Source Page: Modernising support for independent living: the health and disability green paper
Document: Modernising support for independent living: the health and disability green paper (PDF)

Found: Modernising support for independent living: the health and disability green paper


Non-Departmental Publication (News and Communications)
Medicines and Healthcare products Regulatory Agency

Apr. 29 2024

Source Page: Outcome of MHRA review of neuropsychiatric reactions with montelukast
Document: Outcome of MHRA review of neuropsychiatric reactions with montelukast (webpage)

Found: Patients should immediately speak to their prescriber or seek urgent medical attention if neuropsychiatric


Non-Departmental Publication (News and Communications)
Medicines and Healthcare products Regulatory Agency

Apr. 29 2024

Source Page: Men on finasteride asked to stay vigilant for possible psychiatric and sexual side effects
Document: Men on finasteride asked to stay vigilant for possible psychiatric and sexual side effects (webpage)

Found: Men on finasteride asked to stay vigilant for possible psychiatric and sexual side effects


Non-Departmental Publication (News and Communications)
Medicines and Healthcare products Regulatory Agency

Apr. 29 2024

Source Page: Letters and medicine recalls sent to healthcare professionals in March 2024
Document: Tresiba® FlexTouch® 100 U/mL solution for injection (insulin degludec): Supply Shortage in the UK and Tresiba® FlexTouch® 200 U/mL solution for injection (insulin degludec): Medication error (PDF)

Found: Letters and medicine recalls sent to healthcare professionals in March 2024